Posted Feb. 5, 2013 at 9:47 a.m.

Premium Lock PPD adds three drug development executives

Published: 2013-02-05 09:47:27
Updated: 2013-02-05 09:47:27

Print this blog post
PPD PDD

The privately held firm, which is based in Wilmington and operates a facility in the Triangle, says it has added leaders in three new areas of therapeutic focus:

  • Daniel J. Burch, MD,, central nervous system
  • Puneet Mohan, MD, cardiovascular/metabolism
  • Alan M. Solinger, MD, rheumatology/immunology.

“In today’s environment, we are partnering with clients on complex drug development strategy and providing medical and scientific expertise that extends beyond traditional clinical trial implementation,” said Rob Dow, the global head of medical affairs for PPD and former head of global drug development at F. Hoffmann-La Roche. He leads PPD’s global product development team of six therapeutic areas. “These experts have held senior leadership roles in top biopharma companies, and their expertise will bring added strategic value to our clients," Dow said.

 

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2013 WRAL Tech Wire. All rights reserved.

Log in or upgrade to view WRALTechWire Insider content


To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Jim Roberts
Entrepreneurship
Scroll